pakistan
Foundayo: Obesity pill tops 7,000 prescriptions in fourth week
Key takeaways
- Add ARY News on Google AAResize Eli Lilly’s new weight-loss pill, Foundayo, was prescribed 7,335 times in the US in the fourth week, a modest uptake compared to rival Novo Nordisk’s Wegovy pill, analysts said.
- Wegovy pill, launched in January, has the first-mover advantage in the oral weight-loss drug market over Foundayo that was introduced a few months later in April.
- Investors are betting that the next generation of weight-loss pills will expand the market to millions of patients and help counter pricing pressure.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize Eli Lilly’s new weight-loss pill, Foundayo, was prescribed 7,335 times in the US in the fourth week, a modest uptake compared to rival Novo Nordisk’s Wegovy pill, analysts said.
Wegovy pill, launched in January, has the first-mover advantage in the oral weight-loss drug market over Foundayo that was introduced a few months later in April.
RBC Capital Markets analyst Trung Huynh said while Foundayo’s prescription numbers were weaker, “we’re beginning to see investors looking past initial weekly script tracking metrics as the barometer for Foundayo’s future potential.”
Article preview — originally published by ARY News. Full story at the source.
Read full story on ARY News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from ARY News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop